BioScrip shows progress
ELMSFORD, N.Y. – BioScrip today reported third quarter revenues from continuing operations of $247.3 million, a 6.8% increase over the same period last year. Gross profit was $63.1 million, a 3.9% increase, and net loss was $24.2 million, the company reported. BioScrip announced last quarter that it was refocusing on its core infusion business. It sold its non-core pharmacy benefit management business for $25 million, and reduced its workforce by 12%.